About Aminoacylase-1
Aminoacylase-1 (ACY1) is a protein
from Homo sapiens identified by UniProt accession
Q03154, 408 residues long.
MolForge cross-references it against 0 known binders and
138 disease associations.
Target properties
| Protein name | Aminoacylase-1 |
| UniProt accession | Q03154 |
| Gene | ACY1 |
| Organism | Homo sapiens |
| Length | 408 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (138)
Diseases linked to this target (Open Targets).
- Aminoacylase 1 deficiency · score 0.77
- Neurological conditions associated with aminoacylase 1 deficiency · score 0.69
- Intellectual disability · score 0.47
- IGF-1 measurement · score 0.43
- genetic disorder · score 0.38
- N-acetylmethionine measurement · score 0.37
- toxic encephalopathy · score 0.37
- inborn aminoacylase deficiency · score 0.27
- neurodegenerative disease · score 0.22
- body height · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q03154-F1 | alphafold | PREDICTED | 96.41 | — |
Amino-acid sequence (408 residues)
MTSKGPEEEH PSVTLFRQYL RIRTVQPKPD YGAAVAFFEE TARQLGLGCQ KVEVAPGYVV TVLTWPGTNP TLSSILLNSH TDVVPVFKEH WSHDPFEAFK DSEGYIYARG AQDMKCVSIQ YLEAVRRLKV EGHRFPRTIH MTFVPDEEVG GHQGMELFVQ RPEFHALRAG FALDEGIANP TDAFTVFYSE RSPWWVRVTS TGRPGHASRF MEDTAAEKLH KVVNSILAFR EKEWQRLQSN PHLKEGSVTS VNLTKLEGGV AYNVIPATMS ASFDFRVAPD VDFKAFEEQL QSWCQAAGEG VTLEFAQKWM HPQVTPTDDS NPWWAAFSRV CKDMNLTLEP EIMPAATDNR YIRAVGVPAL GFSPMNRTPV LLHDHDERLH EAVFLRGVDI YTRLLPALAS VPALPSDS
Explore Aminoacylase-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets